FTC orders Abbott to divest 2 Alere medical devices after $8.3B acquisition

The Federal Trade Commission on Tuesday ordered Abbott Laboratories to divest two medical device product lines to settle a complaint that the company's $8.3 billion acquisition of Alere is anticompetitive.

Under the settlement, Abbott will divest the rights and assets for its line of point-of-care blood gas testing systems to Siemens Aktiengelsellschaft and sell its point-of-care cardiac marker testing systems to Quidel Corporation. Abbott will also hand over two Ottawa, Canada-based facilities to Siemens and one San Diego-based facility to Quidel.

Abbott completed its acquisition of Alere in October. The FTC ruled the acquisition would likely hinder competition for these two types of medical devices in a September complaint.

More articles on supply chain:

Prime Healthcare taps HealthTrust for GPO services
Acorda Therapeutics halts Parkinson's drug trials after 5 patient deaths
Cardinal Health to sell Chinese distribution business to Shanghai Pharma

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months